Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash & Equivalents (2016 - 2026)

Cytosorbents filings provide 16 years of Cash & Equivalents readings, the most recent being $6.2 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 90.52% to $6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.2 million, a 90.52% increase, with the full-year FY2025 number at $6.2 million, up 90.52% from a year prior.
  • Cash & Equivalents hit $6.2 million in Q4 2025 for Cytosorbents, down from $7.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $68.5 million in Q1 2021 to a low of $1.7 million in Q2 2023.
  • Median Cash & Equivalents over the past 5 years was $12.9 million (2023), compared with a mean of $23.5 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 94.36% in 2023 and later soared 397.57% in 2024.
  • Cytosorbents' Cash & Equivalents stood at $52.1 million in 2021, then tumbled by 57.53% to $22.1 million in 2022, then crashed by 36.19% to $14.1 million in 2023, then crashed by 76.79% to $3.3 million in 2024, then surged by 90.52% to $6.2 million in 2025.
  • The last three reported values for Cash & Equivalents were $6.2 million (Q4 2025), $7.5 million (Q3 2025), and $10.2 million (Q2 2025) per Business Quant data.